The tropical parasitic diseases are responsible for staggering morbidity and millions of deaths every year, especially in the tropical regions of the word. Although incidences of these diseases are mostly centered in tropical regions the socioeconomic and public health impacts of tropical parasitic diseases are global. Emergence and spread of drug-resistant and more virulent strains of the parasites have further intensified the problem. Despite of the heavy burden on humanity the tropical parasitic diseases have been mostly ignored in relation to advances in modern drug discovery and only few new antipatasitic drugs have been developed during last several years. Improved global attention with increasing funding opportunities through public and non-profit organizations as well as emergence of public-private partnerships for development of strategies to monitor, treat, control and eliminate neglected tropical parasitic diseases have generated.
This conference shall focus on multidisciplinary efforts directed against control, treatments and elimination of neglected parasitic diseases. Scientific sessions will be organized specifically (but not limited to) focusing on (1) Social, economic and community-based programs in neglected tropical infectious diseases (2) Drug Resistance: Monitoring, treatment and containment programs (3) Translational research: from bench-side to bed-side (4) Enriching the drug-discovery pipeline- Structural biology/ Molecular biology and therapeutics; Chemical biology/ Medicinal chemistry and therapeutics and In vitro/in vivo pharmacology and efficacy models.
This conference shall focus on multidisciplinary efforts directed against control, treatments and elimination of neglected parasitic diseases. Scientific sessions will be organized specifically (but not limited to) focusing on (1) Social, economic and community-based programs in neglected tropical infectious diseases (2) Drug Resistance: Monitoring, treatment and containment programs (3) Translational research: from bench-side to bed-side (4) Enriching the drug-discovery pipeline- Structural biology/ Molecular biology and therapeutics; Chemical biology/ Medicinal chemistry and therapeutics and In vitro/in vivo pharmacology and efficacy models.
